Placebo effect in Obsessive-Compulsive Disorder (OCD). Placebo response and placebo responders in OCD: The trend over time (Q58113540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

title

Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

obsessive-compulsive disorder

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Gabriele Sani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

Georgios Demetrios Kotzalidis

30 April 2020

object named as

Georgios D Kotzalidis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Maurizio Simmaco

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Lucia Pancheri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Valeria Savoja

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Ilaria Cuomo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Lavinia De Chiara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Chiara Rapinesi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Roberto Brugnoli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Marco Paolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Ida Gualtieri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Alessio Mosca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Maurizio Pompili

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

On Behalf Of The Sapienza Group For The Study Of The Placebo Effect In Psychiatric Disorders

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Paolo Girardi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

language of work or name

English

0 references

publication date

1 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

Current Neuropharmacology

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

741-774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder

30 April 2020

cites work

1 reference

12 December 2020

Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies

1 reference

12 December 2020

Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial

1 reference

12 December 2020

A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder

1 reference

12 December 2020

A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy

1 reference

12 December 2020

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

1 reference

12 December 2020

Suicidal children grow up: demographic and clinical risk factors for adolescent suicide attempts

1 reference

12 December 2020

A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory

1 reference

12 December 2020

Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo

1 reference

12 December 2020

Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients

1 reference

12 December 2020

Clomipramine in obsessive-compulsive disorder

1 reference

12 December 2020

Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels

1 reference

12 December 2020

Early response with clomipramine in obsessive compulsive disorder--a placebo controlled study

1 reference

12 December 2020

Absence of placebo response in obsessive-compulsive disorder

1 reference

12 December 2020

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

1 reference

12 December 2020

The Yale-Brown Obsessive Compulsive Scale. II. Validity

1 reference

12 December 2020

Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients

1 reference

12 December 2020

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

1 reference

12 December 2020

Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder

1 reference

12 December 2020

Fluvoxamine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and on obsessional symptoms

1 reference

12 December 2020

Effects of imipramine on depression and obsessive-compulsive symptoms

1 reference

12 December 2020

Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II.

1 reference

12 December 2020

Fluoxetine treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study

1 reference

12 December 2020

Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial

1 reference

12 December 2020

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder

1 reference

12 December 2020

Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.

1 reference

12 December 2020

A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

12 December 2020

Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group

1 reference

12 December 2020

Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.

1 reference

12 December 2020

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

12 December 2020

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Inositol treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

1 reference

12 December 2020

Placebo-controlled trial of fluoxetine and phenelzine for obsessive- compulsive disorder

1 reference

12 December 2020

Controlled trial of exposure and response prevention in obsessive–compulsive disorder

1 reference

12 December 2020

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

12 December 2020

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

1 reference

12 December 2020

Episodic course in obsessive-compulsive disorder

1 reference

12 December 2020

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial

1 reference

12 December 2020

Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder

1 reference

12 December 2020

Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

Do medical devices have enhanced placebo effects?

1 reference

12 December 2020

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

1 reference

12 December 2020

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial

1 reference

12 December 2020

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

1 reference

12 December 2020

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

1 reference

12 December 2020

Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial

1 reference

12 December 2020

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control

1 reference

12 December 2020

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

12 December 2020

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

1 reference

12 December 2020

Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder

1 reference

12 December 2020

Assessment of symptom exacerbations in a longitudinal study of children with Tourette's syndrome or obsessive-compulsive disorder

1 reference

12 December 2020

Fluoxetine in children and adolescents with OCD: a placebo-controlled trial

1 reference

12 December 2020

A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

1 reference

12 December 2020

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

1 reference

12 December 2020

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

12 December 2020

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

1 reference

12 December 2020

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

1 reference

12 December 2020

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder

1 reference

12 December 2020

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

1 reference

12 December 2020

Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

1 reference

12 December 2020

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder

1 reference

12 December 2020

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

12 December 2020

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

1 reference

12 December 2020

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

1 reference

12 December 2020

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder

1 reference

12 December 2020

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study

1 reference

12 December 2020

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

1 reference

12 December 2020

A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine

1 reference

12 December 2020

St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study

1 reference

12 December 2020

Are placebo-controlled trials still important for obsessive compulsive disorder?

1 reference

12 December 2020

Sham device versus inert pill: randomised controlled trial of two placebo treatments

1 reference

12 December 2020

Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients

1 reference

12 December 2020

Escitalopram prevents relapse of obsessive-compulsive disorder

1 reference

12 December 2020

Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study

1 reference

12 December 2020

A systematic review of placebo response in studies of bipolar mania

1 reference

12 December 2020

Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.

1 reference

12 December 2020

Increasing rates of placebo response over time in mania studies.

1 reference

12 December 2020

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

1 reference

12 December 2020

Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis

1 reference

12 December 2020

Efficacy of aqueous extract of Echium amoenum in treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

1 reference

12 December 2020

A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder

1 reference

12 December 2020

A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder

1 reference

12 December 2020

Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder

1 reference

12 December 2020

1 reference

12 December 2020

Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

1 reference

12 December 2020

Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial

1 reference

12 December 2020

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration

1 reference

12 December 2020

Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study

1 reference

12 December 2020

Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).

1 reference

12 December 2020

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

1 reference

12 December 2020

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

1 reference

12 December 2020

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept

1 reference

12 December 2020

Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

1 reference

12 December 2020

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial

1 reference

12 December 2020

Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder

1 reference

12 December 2020

Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.

1 reference

12 December 2020

12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder

1 reference

12 December 2020

Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants

1 reference

12 December 2020

Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial

1 reference

12 December 2020

Use of placebo controls in the evaluation of surgery: systematic review

1 reference

12 December 2020

Does d-Cycloserine Augmentation of CBT Improve Therapeutic Homework Compliance for Pediatric Obsessive-Compulsive Disorder?

1 reference

12 December 2020

Placebo response in antipsychotic clinical trials: a meta-analysis

1 reference

12 December 2020

Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD

1 reference

12 December 2020

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial

1 reference

12 December 2020

Increasing placebo responses over time in U.S. clinical trials of neuropathic pain

1 reference

12 December 2020

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study

1 reference

12 December 2020

Factors contributing to the increasing placebo response in antidepressant trials.

1 reference

12 December 2020

From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings

1 reference

12 December 2020

N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study.

1 reference

12 December 2020

Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial

1 reference

12 December 2020

Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial

1 reference

12 December 2020

d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder

1 reference

12 December 2020

The effect of treatment on quality of life and functioning in OCD.

1 reference

12 December 2020

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

1 reference

12 December 2020

Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: A meta-analysis

1 reference

12 December 2020

L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study

1 reference

12 December 2020

Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013.

1 reference

12 December 2020

Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.

1 reference

12 December 2020

Buprenorphine augmentation improved symptoms of OCD, compared to placebo - Results from a randomized, double-blind and placebo-controlled clinical trial

1 reference

12 December 2020

Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial

1 reference

12 December 2020

Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016.

1 reference

12 December 2020

10.2174/1570159X16666181026163922

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

PubMed publication ID

30370851

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30370851%20AND%20SRC:MED&resulttype=core&format=json